Learn about our Sample to Insight solutions for inherited disorders This year at the European Society for Human Genetics (ESHG) 2023 Annual Meeting, QIAGEN will be at booth #472 premiering our new barrier-breaking Sample to Insight workflow for inherited disease NGS testing—a fast, cheap, ultra-precise panel to report pipeline. Learn more about our products and solutions […]
In this 90-minute training on QIAGEN OmicSoft and Ingenuity Pathway Analysis (IPA), we’ll cover how to easily query inflammatory conditions related to public data (GEO, SRA and more) to: • Rapidly query and identify public datasets that fit our search criteria • Discover and validate biomarker expression in disease tissue, different treatments and response groups […]
Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases Clinical exome testing is revolutionizing the diagnosis […]
Watch NowIn this training, you will learn how to analyze viral samples using QIAGEN CLC Genomics Workbench. This webinar will focus on bioinformatics workflows and data interpretation using H5N1 as an […]
Watch NowMore and more biopharma and academic groups are looking to process a large number of samples simultaneously or for a quicker turnaround time. This webinar will introduce a flexible and […]
Watch NowThere is a strong interest in the scientific community to use public (GEO, SRA, TCGA, LINCS, etc.) omics (RNA-seq, scRNA-seq, microarray, proteomics, etc.) data for a variety of discoveries. This […]
Watch NowYou’re invited to attend the 2024 Clinician’s Roundtable, a virtual event where medical directors and oncologists will discuss how to better interpret genomic test results to tailor treatment strategies for […]
Watch NowIngenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships […]
Watch Now
